Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Jun 25;9(1):9248.
doi: 10.1038/s41598-019-45110-5.

The impact of levodopa therapy-induced complications on quality of life in Parkinson's disease patients in Singapore

Affiliations
Clinical Trial

The impact of levodopa therapy-induced complications on quality of life in Parkinson's disease patients in Singapore

Jonathan Wu et al. Sci Rep. .

Abstract

The objective of this study was to investigate the impact of levodopa therapy-induced complications on the quality of life (QoL) of Parkinson's disease (PD) patients in Singapore over a 1-year follow-up period. 274 PD patients were prospectively recruited, of which 78 patients completed the follow-up. Patients were evaluated on: (1) motor symptoms, (2) non-motor symptoms, (3) levodopa therapy-induced complications and (4) QoL. Levodopa-induced complications including dyskinesia and OFF symptoms occurred in 13.5% and 55.9% of the study population, respectively. In patients who completed the 1-year follow-up, there was a trend suggestive of increasing dyskinesia duration, more disabling dyskinesia as well as longer, more sudden and unpredictable OFF periods. There was a significant decline in the overall QoL at follow-up, in particular, activities of daily living, emotional well-being, cognition and communication domains were the most affected. The multivariable analysis demonstrated that worsening of UPDRS IV total score over 1-year interval was associated with worsening in PDQ-Summary Index score (d = 0.671, p = 0.014). In conclusion, levodopa-induced complications had significant adverse impacts on QoL. This study substantiates the importance for clinicians to closely monitor and promptly manage levodopa therapy-induced complications that may arise in patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Alves G, Forsaa EB, Pedersen KF, Dreetz GM, Larsen JP. Epidemiology of Parkinson’s disease. J. Neurol. 2008;255:18–32. doi: 10.1007/s00415-008-5004-3. - DOI - PubMed
    1. GBD 2016 Parkinson’s disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 17, 939-953 (2018). - PMC - PubMed
    1. Kianirad Y, Simuni T. Novel Approaches to Optimization of Levodopa Therapy for Parkinson’s disease. Curr. Neurol. Neurosci. Rep. 2016;16:34. doi: 10.1007/s11910-016-0635-8. - DOI - PubMed
    1. Thanvi BR, Lo TC. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad. Med. J. 2004;80:452–458. doi: 10.1136/pgmj.2003.013912. - DOI - PMC - PubMed
    1. Goetz CG, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 2008;23:2129–2170. doi: 10.1002/mds.22340. - DOI - PubMed

Publication types